

New Ligands Bearing Chiral Bioactive Fragments

Abderrahim Khatyr and Raymond Ziessel*

Laboratoire de Chimie, d'Electronique et de Photonique Moléculaires, Associé au CNRS ESA-7008, Ecole de Chimie, Matériaux, Polymères de Strasbourg (ECPM), 25 rue Becquerel, 67087 Strasbourg Cedex 02, France

Supplementary Materials

General Procedure for the Preparation of the Tyrosine precursors.

3-Iodo-L-(tyrosine-)methylester-benzoylamide (1). To a suspension 0.200 g (0.560 mmol) of 3-iodo-L-tyrosine methyl ester hydrochloride in 20 mL of CH_2Cl_2 , 0.156 mL (1.120 mmol) of Et_3N was added. After dissolution (0.5 h), 0.065 mL (0.560 mmol) of benzoyl chloride was added. The reaction mixture was stirred at room temperature during 20 h. Purification was performed by chromatography on alumina eluting with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (0 to 2 %) as eluant. The analytically pure white compound was obtained after a recrystallization in CH_2Cl_2 /hexane affording 0.219 g of **1** (92 %); ^1H NMR (CDCl_3) δ 3.12 (m, CH_2 , 2H), 3.76 (s, OCH_3 , 3H), 5.01 (m, CH, 1H), 5.65 (s, 1H), 6.75 (d, $^3J_{\text{H-H}} = 7.3$ Hz, 1H), 6.84 (m, 2H), 7.45 (m, 4H), 7.71 (d, $^3J_{\text{H-H}} = 6.95$ Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3) δ 36.4, 52.6, 53.7, 84.9, 115.2, 127.0, 128.6, 129.2, 130.6, 132.0, 133.4, 139.3, 154.8, 167.4, 172.0; FT-IR (KBr, cm^{-1}) 3425 (s), 2945 (m), 2356 (w), 1738 (s), 1641 (s), 1603 (w), 1575 (w), 1535 (s), 1487 (m), 1416 (m), 1290 (m), 1219 (s), 1024 (w), 714 (m); UV-vis (CH_2Cl_2): λ nm (ϵ , $\text{M}^{-1}\text{cm}^{-1}$) 281 (2,800), 289 (2,500); FAB $^+$ m/z (nature of peak, relative intensity) 426 ($[\text{M}+\text{H}]^+$, 100), 367 ($[\text{M}-\text{CO}_2\text{CH}_3+\text{H}]^+$, 30); $[\alpha]_{\text{D}} = +11^\circ$ (in CH_2Cl_2 , concentration of 5 gL^{-1}); Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_4\text{I}$: C, 48.02; H, 3.79; N, 3.29. Found: C, 47.89; H, 3.57; N, 2.99.

3-Iodo-4-benzoyl-L-(tyrosine-methylester-benzoylamide) (2). Following the procedure described above for **1** using 0.200 g (0.560 mmol) of 3-iodo-L-tyrosine methyl ester hydrochloride 3-iodo-L-tyrosine methyl ester hydrochloride in 40 mL of CH_2Cl_2 , 0.468 mL (3.356 mmol) of Et_3N and 0.064 mL (0.560 mmol) of benzoyl chloride. The reaction mixture was stirred at room temperature during 8 h. Purification was performed by chromatography on alumina eluting with CH_2Cl_2 as eluant and and afforded 0.216 g of **2** (73 %); ^1H NMR (CDCl_3) δ 3.28 (m, CH_2 , 2H), 3.81 (s, OCH_3 , 3H), 5.11 (m, CH, 1H), 6.71 (d, $^3J_{\text{H-H}} = 6.9$ Hz, 1H), 7.20 (m, 2H), 7.52 (m, 5H), 7.69 (m, 4H), 8.26 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3) δ 36.8, 52.6, 53.5, 90.4, 123.0, 127.0, 128.6, 128.7, 129.0, 130.3, 130.4, 131.9, 133.7, 133.9, 135.7, 140.2, 150.5, 164.2, 167.0, 171.7; FT-IR (KBr, cm^{-1}) 3328 (s), 2944 (m), 2362 (w), 1733 (s), 1638 (s), 1602 (w), 1578 (w), 1527 (s), 1487 (m), 1449 (m), 1373 (m), 1320 (m), 1260 (s), 1203 (s), 1160 (m), 1081 (m), 1063 (m), 705 (m); UV-vis (CH_2Cl_2): λ nm (ϵ , $\text{M}^{-1}\text{cm}^{-1}$) 269 (3,500); FAB $^+$ m/z (nature of peak, relative intensity) 530 ($[\text{M}+\text{H}]^+$, 100), 425 ($[\text{M}-\text{PhCO}+\text{H}]^+$, 20), 319 ($[\text{M}-2\text{PhCO}+\text{H}]^+$, 5); $[\alpha]_{\text{D}} = +17^\circ$ (in CH_2Cl_2 , concentration of 5 gL^{-1}); Anal. Calcd for $\text{C}_{24}\text{H}_{20}\text{NO}_5\text{I}$: C, 54.46; H, 3.81; N, 2.65. Found: C, 54.15; H, 3.62; N, 2.47.

General Procedure for the Preparation of the monotopic and ditopic ligands.

A Schlenk flask was charged with 3-iodo-L-tyrosine derivatives **1** or **2** and 4'-ethynyl-2,2':6',2''-terpyridine, 5-ethynyl-2,2'-bipyridine, 6,2''-diethynyl-2,2':6',2''-terpyridine, 5,5'-diethynyl-2,2'-bipyridine or 5-(2,2'-bipyridine-5-yl-ethynyl)-5'-ethynyl-2,2'-bipyridine in argon degassed THF, then ($[\text{Pd}(\text{PPh}_3)_2\text{Cl}_2]$ and CuI) (6 mol %) were added as a solid and finally argon degassed diisopropylamine was added. The solution was allowed to stir during 3 days at room temperature. After consumption of the starting material (determined by TLC), the solvent was evaporated and the residue was purified by chromatography on alumina using dichloromethane with gradient of methanol.

4'-{(3-Ethynyl-yl)-L-(tyrosine-methylester-benzoylamide)}-2,2':6',2''-

terpyridine (3a). This ligand was prepared according the procedure general, from 0.110 g (0.258 mmol) of 3-iodo-L-tyrosine methyl ester benzyl amide **1** in 10 mL of THF, 0.080 g (0.310 mmol) of 4'-ethynyl-2,2':6',2''-terpyridine, 0.010 g (0.014 mmol) of $[\text{Pd}(\text{PPh}_3)_2\text{Cl}_2]$, 0.003 g (0.016 mmol) of CuI and 3 mL of diisopropylamine. Purification was performed by chromatography on alumina with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (0 to 4 %) as eluant and afforded 0.060 g of **3a** (42 %); ^1H NMR (CDCl_3) δ 3.37 (m, CH_2 , 2H), 3.79 (s, OCH_3 , 3H), 5.12 (m, CH, 1H), 6.72 (d, $^3J_{\text{H-H}} = 7.8$ Hz, 1H), 7.11 (d, $^3J_{\text{H-H}} = 8.4$ Hz, 1H), 7.41 (m, 8H), 7.74 (dd, $^3J_{\text{H-H}} = 8.0$ Hz, $^4J_{\text{H-H}} = 1.8$ Hz, 2H), 7.86 (td, $^3J_{\text{H-H}} = 8.0$ Hz, $^4J_{\text{H-H}} = 1.8$ Hz, 2H), 8.62 (dd, $^3J_{\text{H-H}} = 8.0$ Hz, $^4J_{\text{H-H}} = 0.7$ Hz, 2H), 8.73 (m, 2H), 8.83 (m, 2H); FT-IR (KBr, cm^{-1}) 3261 (m), 3057 (m), 2951 (m), 2923 (m), 2854 (m), 1737 (s), 1644 (s), 1608 (s), 1581 (s), 1540 (s), 1466 (s), 1438 (m), 1400 (s), 1347 (w), 1262 (m), 1229 (m), 1177 (w), 1121 (w); FAB $^+$ m/z (nature of peak, relative intensity) 555 ($[\text{M}+\text{H}]^+$, 100), 496 ($[\text{M}-\text{CO}_2\text{CH}_3+\text{H}]^+$, 20). $[\alpha]_{\text{D}} = +41^\circ$ (in CH_2Cl_2 , concentration of 5 gL^{-1}). Anal. Calcd for $\text{C}_{34}\text{H}_{26}\text{N}_4\text{O}_4$: C, 73.63; H, 4.73; N, 10.10. Found: C, 73.43; H, 4.42; N, 9.72.

4'-{(3-Ethynyl-yl)-4-benzoyl-L-(tyrosine-methylester-benzoylamide)}-2,2':6',2''-

terpyridine (3b) This ligand was prepared according the procedure general, from 0.100 g (0.189 mmol) of 3-iodo-4-benzoyl-L-tyrosine methyl ester benzyl amide **2** in 8 mL of THF, 0.058 g (0.227 mmol) of 4'-ethynyl-2,2':6',2''-terpyridine, 0.008 g (0.011 mmol) of $[\text{Pd}(\text{PPh}_3)_2\text{Cl}_2]$, 0.002 g (0.011 mmol) of CuI and 2 mL of diisopropylamine. Purification was performed by chromatography on alumina with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (0 to 10 %) as eluant and afforded 0.061 g of **3b** (49 %); ^1H NMR (CDCl_3) δ 3.23 (m, CH_2 , 2H), 3.82 (s, OCH_3 , 3H), 5.11 (m, CH, 1H), 6.64 (d, $^3J_{\text{H-H}} = 6.7$ Hz, 1H), 6.92 (d, $^3J_{\text{H-H}} = 8.3$ Hz, 1H), 7.11 (d, $^3J_{\text{H-H}} = 8.5$ Hz, 1H), 7.23 (d, $^4J_{\text{H-H}} = 2.0$ Hz, 1H), 7.41 (m, 11H), 7.78 (dd, $^3J_{\text{H-H}} = 7.8$ Hz, $^4J_{\text{H-H}} = 1.7$ Hz, 2H), 7.87 (td, $^3J_{\text{H-H}} = 7.8$ Hz, $^4J_{\text{H-H}} = 1.7$ Hz, 2H), 8.53 (s, 2H), 8.60 (d, $^3J_{\text{H-H}} = 7.8$ Hz, 2H), 8.73 (m, 2H); FT-IR (KBr, cm^{-1}) 3272 (m), 3058 (w), 2954 (m), 2923 (s), 2851 (m), 2211 (w), 1739 (s), 1637 (m), 1576 (s), 1488 (m), 1465 (s), 1391 (s), 1262 (s), 1215 (m), 1177 (m), 891 (w), 792 (s); FAB $^+$ m/z (nature of peak, relative intensity)

659 ($[M+H]^+$, 100), 600 ($[M-CO_2CH_3+H]^+$, 30), 495 ($[M-CO_2CH_3-PhCO+H]^+$, 10). $[\alpha]_D = +49^\circ$ (in CH_2Cl_2 , concentration of 5 gL^{-1}). Anal. Calcd for $C_{41}H_{30}N_4O_5$: C, 74.76; H, 4.59; N, 8.51. Found: C, 74.63; H, 4.42; N, 8.39.

5-((3-Ethynyl-yl)-L-(tyrosine-methylester-benzoylamide))-2,2'-bipyridine

(4a). This ligand was prepared according the procedure general, from 0.090 g (0.212 mmol) of 3-iodo-L-tyrosine methyl ester benzyl amide **1** in 7 mL of THF, 0.046 g (0.255 mmol) of 5-ethynyl-2,2'-bipyridine, 0.009 g (0.012 mmol) of $[Pd(PPh_3)_2Cl_2]$, 0.0023 g (0.012 mmol) of CuI and 1.5 mL of diisopropylamine. Purification was performed by chromatography on alumina with CH_2Cl_2/CH_3OH (0 to 3 %) as eluant and afforded 0.058 g of **4a** (57 %); 1H NMR ($CDCl_3$) δ 3.38 (m, CH_2 , 2H), 3.79 (s, OCH_3 , 3H), 5.12 (m, CH, 1H), 6.61 (d, $^3J_{H-H} = 7.3$ Hz, 1H), 7.08 (m, 3H), 7.47 (m, 4H), 7.80 (m, 4H), 8.22(dd, $^3J_{H-H} = 8.5$ Hz, $^4J_{H-H} = 2.2$ Hz, 1H), 8.47 (td, $^3J_{H-H} = 8.5$ Hz, $^4J_{H-H} = 2.2$ Hz, 2H), 8.71(d, $^3J_{H-H} = 8.4$ Hz, 1H), 9.15 (m, 1H); FT-IR (KBr, cm^{-1}) 3280 (s), 3047 (s), 2947 (s), 2915 (s), 2365 (w), 1748 (s), 1649 (s), 1579 (m), 1536 (s), 1459 (m), 1434 (m), 1260 (m), 1230 (s), 1009 (m), 795 (m); FAB $^+$ m/z (nature of peak, relative intensity) 478 ($[M+H]^+$, 100), 419 ($[M-CO_2CH_3+H]^+$, 50). $[\alpha]_D = +39^\circ$ (in CH_2Cl_2 , concentration of 5 gL^{-1}). Anal. Calcd for $C_{29}H_{23}N_3O_4$: C, 72.94; H, 4.85; N, 8.80. Found: C, 72.62; H, 4.59; N, 8.65.

5-((3-Ethynyl-yl)-4-benzoyl-L-(tyrosine-methylester-benzoylamide))-2,2'-bipyridine (4b).

This ligand was prepared according the general procedure, from 0.307 g (0.580 mmol) of **2**, 0.100 g (0.555 mmol) of 5-ethynyl-2,2'-bipyridine, 0.020 g (0.028 mmol) of $[Pd(PPh_3)_2Cl_2]$, 0.008 g (0.042 mmol) of CuI, in 20 mL of THF and 3.0 mL of diisopropylamine. Purification was performed by chromatography on alumina with CH_2Cl_2/CH_3OH (0 to 10 %) as eluant and afforded 0.194 g of **4b** (60 %); 1H NMR ($CDCl_3$) δ 3.41 (m, CH_2 , 2H), 3.73 (s, OCH_3 , 3H), 5.21 (m, CH, 1H), 6.69 (d, $^3J_{H-H} = 7.2$ Hz, 1H), 7.12 (m, 2H), 7.54 (m, 5H), 7.85 (m, 6H), 8.27 (dd, $^3J_{H-H} = 8.3$ Hz, $^4J_{H-H} = 2.0$ Hz, 1H), 8.33 (m, 2H), 8.54 (td, $^3J_{H-H} = 8.3$ Hz, $^4J_{H-H} = 2.0$ Hz, 2H), 8.79 (d, $^3J_{H-H} = 8.2$ Hz, 1H), 9.26 (m, 1H). FT-IR (KBr, cm^{-1}) 3275 (s), 3051 (s), 2954 (s), 2926 (s), 1752 (s), 1651 (s),

1581 (s), 1536 (m), 1459 (m), 1432 (m), 1241 (s), 999 (m); FAB⁺ m/z (nature of peak, relative intensity) 582 ([M+H]⁺, 100), 523 ([M-CO₂CH₃+H]⁺, 10). [α]_D = + 45° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₃₆H₂₇N₃O₅: C, 74.34; H, 4.68; N, 7.22. Found: C, 74.02; H, 4.31; N, 7.05.

6,6''-{(3-Ethynyl-yl)-L-(tyrosine-methylester-benzoylamide)}-2,2':6',2''

terpyridine (5a). Prepared according to the general procedure from 0.100 g (0.355 mmol) of 2'',6-diethynyl-2,2':6',6''-terpyridine and 0.153 g (0.360 mmol) of **1**, 0.015 g (0.021 mmol) of [Pd(PPh₃)₂Cl₂], 0.007 g (0.036 mmol) of CuI, in THF (25 mL) and diisopropylamine (6 mL). Purification was performed by chromatography column on alumina eluted with a gradient of methanol/CH₂Cl₂ (0 to 10%, v/v) and afforded white powder 0.218 g of ligand **5a** (70%); ¹H NMR (CDCl₃) δ 3.25 (m, CH₂, 4H), 3.79 (s, OCH₃, 6H), 5.12 (m, CH, 2H), 6.75 (d, ³J_{H-H} = 7.1 Hz, 2H), 6.80 (m, 4H), 7.50 (m, 10H), 7.79 (d, ³J_{H-H} = 7.0 Hz, 4H); 8.12 (m, 3H), 8.19 (dd, J = 7.9 Hz, J = 1.0 Hz, 2H), 8.75 (d, J = 8.0 Hz, 2H), 8.80 (dd, J = 7.7 Hz, J = 1.1 Hz, 2H); FT-IR (KBr, cm⁻¹) 2960 (m), 2871 (w), 1739 (s), 1651 (s), 1579 (m), 1437 (m), 1312 (m), 1259 (s), 1152 (s); FAB⁺/MS (m/z) 876 ([M+H]⁺, 100), 817 (M-CO₂CH₃, 35), 758 (M-2CO₂CH₃, 8). [α]_D = + 73° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₅₃H₄₁N₅O₈: C, 72.67; H, 4.72; N, 8.00. Found C, 72.41; H, 4.51; N, 7.76.

6,6''-{(3-Ethynyl-yl)-4-benzoyl-L-(tyrosine-methylester-benzoylamide)}-

2,2':6',2''-terpyridine (5b). Prepared according to general procedure from 0.100 g (0.355 mmol) of 2'',6-diethynyl-2,2':6',6''-terpyridine, 0.196 g (0.370 mmol) of **2**, 0.015 g (0.021 mmol) of [Pd(PPh₃)₂Cl₂], 0.007 g (0.036 mmol) of CuI, in THF (60 mL) and diisopropylamine (6 mL). Purification was performed by chromatography on alumina eluted with a gradient of methanol /CH₂Cl₂ (0 to 15%, v/v) and afforded white powder 0.277 g of ligand **5b** (72%); ¹H NMR (CDCl₃) δ 3.33 (m, CH₂, 4H), 3.86 (s, OCH₃, 6H), 5.21 (m, CH, 2H), 6.75 (d, ³J_{H-H} = 7.0 Hz, 2H), 7.25 (m, 4H), 7.59 (m, 10H), 7.73 (m, 8H), 8.14 (m, 3H), 8.21 (dd, J = 7.8 Hz, J = 1.0 Hz, 2H), 8.33 (m, 4H), 8.75 (d, J = 7.8 Hz, 2H), 8.79 (dd, J = 7.8 Hz, J = 1.2 Hz, 2H); FT-IR (KBr, cm⁻¹) 2969 (m), 2875 (w), 1738 (s), 1639

(m), 1579 (m), 1470 (w), 1436 (m), 1312 (m), 1259 (s), 1162 (s); FAB⁺/MS (m/z) 1084 ([M+H]⁺, 100), 1025 (M-CO₂CH₃, 35), 966 (M-2CO₂CH₃, 6). [α]_D = + 82° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₆₇H₄₉N₅O₁₀: C, 74.23; H, 4.56; N, 6.46. Found C, 74.02; H, 4.33; N, 6.28.

5,5'-((3-Ethynyl-yl)-L-(tyrosine-methylester-benzoylamide))-2,2'-bipyridine (6a). Prepared following the general procedure, from 0.100 g (0.489 mmol) of 5,5'-diethynyl-2,2'-bipyridine, 0.212 g (0.499 mmol) of **1**, 0.020 g (0.028 mmol) [PdCl₂(PPh₃)₂], 0.009 g (0.047 mmol) CuI, 20 mL of THF, and 2 mL of diisopropylamine, to give 0.296 g (76%) of ligand **6a**; ¹H NMR (CDCl₃) δ 3.12 (m, CH₂, 4H), 3.76 (s, OCH₃, 6H), 5.01 (m, CH, 2H), 6.75 (d, ³J_{H-H} = 7.3 Hz, 2H), 6.84 (m, 4H), 7.45 (m, 10H), 7.71 (d, ³J_{H-H} = 6.95 Hz, 4H); 7.85 (dd, J = 8.2 Hz, J = 2.0 Hz, 2H), 8.35 (d, J = 8.2 Hz, 2H), 8.71 (d, J = 2.0 Hz, 2H); IR (KBr, cm⁻¹) 2958 (s), 2161(w), 1750 (s), 1652 (s), 1588 (s), 1531(s), 1457 (s), 1363 (s), 1250 (s), 1220 (s); FAB⁺ m/z 799 ([M+H]⁺, 100), 740 (M-CO₂CH₃, 45), 681 (M-2CO₂CH₃, 15). [α]_D = + 74° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₄₈H₃₈N₄O₈: C, 72.17; H, 4.79; N, 7.01; Found C, 71.86; H, 4.52; N, 6.75.

5,5'-((3-Ethynyl-yl)-4-benzoyl-L-tyrosine-methylester-benzoylamide))-2,2'-bipyridine (6b). Prepared following the general procedure from 0.100 g (0.489 mmol) of 5,5'-diethynyl-2,2'-bipyridine, 0.265 g (0.500 mmol) of **2**, 0.020 g (0.028 mmol) [PdCl₂(PPh₃)₂], 0.009 g (0.047 mmol) CuI, 30 mL of THF, and 5 mL of diisopropylamine, to give 0.364 g (74%) of ligand **6b**; ¹H NMR (CDCl₃) δ 3.32 (m, CH₂, 4H), 3.96 (s, OCH₃, 6H), 5.36 (m, CH, 2H), 6.98 (d, ³J_{H-H} = 7.0 Hz, 2H), 7.42 (m, 4H), 7.59 (m, 10H), 7.73 (m, 8H), 7.93 (dd, J = 8.6 Hz, J = 1.8 Hz, 2H), 8.39 (m, 4H), 8.55 (d, J = 8.6 Hz, 2H), 8.83 (d, J = 2.0 Hz, 2H); IR (KBr, cm⁻¹) 2958 (s), 2161(w), 1754 (s), 1652 (s), 1588 (s), 1531(s), 1457 (s), 1363 (s), 1250 (s), 1220 (s); FAB⁺ m/z 1007 ([M+H]⁺, 100), 948 (M-CO₂CH₃, 45), 889 (M-2CO₂CH₃, 15). [α]_D = + 88° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₆₂H₄₆N₄O₁₀: C, 73.95; H, 4.60; N, 5.56; Found C, 73.66; H, 4.32; N, 5.31.

5-(2,2'-Bipyridine-5-yl-ethynyl)-5'-{(3-ethynyl-yl)-L-(tyrosine-methylester benzoylamide)}-2,2'-bipyridine (8a). The compound was prepared according to the general procedure, from 0.100 g (0.279 mmol) of 5-(2,2'-bipyridine-5-yl-ethynyl)-5'-ethynyl-2,2'-bipyridine, 0.119 g (0.280 mmol) of **1**, 0.012 g (0.017 mmol) [PdCl₂(PPh₃)₂], 0.005 g (0.026 mmol) CuI, 30 mL of THF and 5 mL of diisopropylamine. Purification was performed by chromatography on alumina with CH₂Cl₂/CH₃OH (0 to 15%) as eluant and afforded 0.090 g of **7a** (49 %); ¹H NMR (CDCl₃) δ 3.26 (m, CH₂, 2H), 3.83 (s, OCH₃, 3H), 5.18 (m, CH, 1H), 6.77 (d, ³J_{H-H} = 7.5 Hz, 1H), 6.93 (m, 2H), 7.39 (dd, J = 5.0 Hz, J = 1.1 Hz, 1H), 7.50 (m, 4H), 7.82 (d, ³J_{H-H} = 7.0 Hz, 2H), 7.96 (m, 4H), 8.52 (m, 5H), 8.88 (m, 1H), 8.86 (m, 1H), 8.94 (m, 2H); FT-IR (KBr, cm⁻¹) 3460 (s), 2923 (m), 2195 (w, ν_{C≡C}), 1754 (s), 1658 (s), 1601 (m), 1460 (s), 1313 (m), 1243 (m), 1109 (s), 841 (s); FAB⁺ 656 ([M+H]⁺, 100), 597 (M-CO₂CH₃, 25). [α]_D = + 40° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₄₁H₂₉N₅O₄: C, 75.10; H, 4.46; N, 10.68. Found: C, 74.95; H, 4.22; N, 10.36.

5-(2,2'-Bipyridine-5-yl-ethynyl)-5'-{(3-ethynyl-yl)-4-benzoyl-L-(tyrosine-methylester-benzoylamide)}-2,2'-bipyridine (8b). The compound was prepared according to the general procedure, from 0.100 g (0.279 mmol) of 5-(2,2'-bipyridine-5-yl-ethynyl)-5'-ethynyl-2,2'-bipyridine, 0.148 g (0.280 mmol) of **2**, and 0.012 g (0.017 mmol) [PdCl₂(PPh₃)₂], 0.005 g (0.026 mmol) CuI, 40 mL of THF and 10 mL of diisopropylamine. Purification was performed by chromatography on alumina with CH₂Cl₂/CH₃OH (0 to 15%) as eluant and afforded 0.106 g of **7b** (50 %); ¹H NMR (CDCl₃) δ 3.35 (m, CH₂, 2H), 3.85 (s, OCH₃, 3H), 5.26 (m, CH, 1H), 6.85 (d, ³J_{H-H} = 7.2 Hz, 1H), 7.38 (m, 2H), 7.54 (dd, J = 5.0 Hz, J = 1.4 Hz, 1H), 7.65 (m, 5H), 7.84 (m, 4H), 7.98 (m, 4H), 8.32 (m, 2H); 8.48 (m, 4H), 8.85 (m, 1H), 8.96 (m, 1H), 9.02 (m, 2H); FT-IR (KBr, cm⁻¹) 3460 (s), 2923 (m), 2195 (w, ν_{C≡C}), 1757 (s), 1654 (s), 1601 (m), 1460 (s), 1313 (m), 1243 (m), 1109 (s), 841 (s); UV-vis (CH₂Cl₂): λ nm (ε, M⁻¹cm⁻¹) 269 (1,600), 341 (11,200), 361 (9,200); FAB⁺ 760 ([M+H]⁺, 100), 701 (M-CO₂CH₃, 33). [α]_D = + 43° (in CH₂Cl₂, concentration of 5 gL⁻¹). Anal. Calcd for C₄₈H₃₃N₅O₅: C, 75.88; H, 4.38; N, 9.22. Found: C, 75.62; H, 4.05; N, 9.02.